Business
Biosergen publishes 2024 annual report
Biosergen publishes 2024 annual
About this update from Biosergen Ab
[{"type":"text","content":"April 30, 2025: Biosergen AB (\"Biosergen\" or the \"Company\") hereby announces that the 2022 annual report is available on the company website www.biosergen.net (https://www.biosergen.net/investor-relations#Financial%20Reports)For further information about Biosergen, please contact:Tine Olesen, CEO\nTelefon: +45 3135 5707\nE-mail: [email protected] Laursen, CFO\nTelephone: +45 4014 5059\nE-mail: [email protected]\n\nBolagets Certified Adviser är Carnegie Investment Bank AB (publ).ABOUT BIOSERGEN\nBiosergen is a clinical stage biotechnology company advancing the treatment of life-threatening fungal infections. Biosergen' s mission is to develop the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. Unlike conventional options, BSG005 potential is to eliminate fungal infections rather than just slowing their growth, reducing the risk of resistance. Consequently, BSG005 is set to become a new first line treatment choice for resistant and/or difficult to treat invasive fungal infections, offering a safer and more effective solution where current therapies fall short ultimately saving thousands of lives of lives of immune-compromised cancer, transplant and AIDS patients every year.https://news.cision.com/biosergen-ab/r/biosergen-publishes-2024-annual-report,c4143285https://mb.cision.com/Main/20568/4143285/3421279.pdfhttps://mb.cision.com/Public/20568/4143285/af6978b384ec7ebc.pdf(c) 2025 Cision. All rights reserved., source Press Releases - English","length":3096,"tagName":"div"}]